Question · asked by 1 review
Gabapentin vs placebo: Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved
- Population
- people with diabetic peripheral neuropathy
- Intervention
- Gabapentin
- Comparison
- placebo
- Outcome
- Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Gabapentin vs placebo Any definition of moderate benefit (at least 30% pain intensity reduction or PGIC much or very much improved) · adults with peripheral diabetic neuropathy Gabapentin for chronic neuropathic pain in adults (2017) · Cochrane Headline outcomes only | no estimate extracted | 7 studies · 1439 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Gabapentin for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.